NantKwest, Inc (NK)

Etorro trading 970x250
NantKwest, Inc (NK) Logo

About NantKwest, Inc

NantKwest, Inc., a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and Nant cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells. It is also developing high-affinity natural killer (haNK) product candidates primarily for the treatment of various cancers; and tank and t-haNK product candidates to treat solid tumors. NantKwest, Inc. has a co-development agreement with Altor BioScience, LLC to collaborate on the development of therapeutic applications combining the company’s proprietary natural killer cells with Altor’s N-801 and/or N-803 products; collaboration with Be The Match BioTherapies for the development of cell therapy to prevent COVID-19 deaths; and strategic alliance with Immunitybio. It also has a collaboration with CBR Systems, Inc. to develop a COVID-19 treatment leveraging newborn stem cells. The company was formerly known as Conkwest, Inc. and changed its name to NantKwest, Inc. in July 2015. NantKwest, Inc. was founded in 2002 and is headquartered in San Diego, California. Address: 3530 John Hopkins Court, San Diego, CA, United States, 92121

NantKwest, Inc News and around…

Latest news about NantKwest, Inc (NK) common stock and company :

CytoImmune Therapeutics Hosting Key Opinion Leader Webinar on Human Natural Killer (NK) Cell Immunotherapy
19 Jul, 2021 FinancialContent
Motus GI Appoints Experienced Financial Biotech Executive, Sonja Nelson, to its Board of Directors and as Chair of Audit Committee
23 Jun, 2021 FinancialContent
Shanghai ImmuneOnco Raises $89 Million for Cancer Immunotherapies
25 Mar, 2021 FinancialContent

Shanghai ImmuneOnco Biopharma completed an $89 million Series C funding led by Guangdong's Greater Homeland Bay Area Investments and Lilly Asia Ventures. Founded in 2015, ImmuneOnco has established discovery platforms that exploit two types of innate immune cells: macrophages and natural killer (NK) cells. The company has been approved to start two clinical trials: IMM01, an anti-CD47 fusion protein, was approved in China, and IMM0306, a bispecific antibody targeting CD47 and CD20, was approved in the US. More details.... Share this with colleagues:

82 Biggest Movers From Yesterday
10 Mar, 2021 FinancialContent

Gainers INVO Bioscience, Inc. (NASDAQ: INVO) shares surged 202.3% to close at $9.40 on Tuesday after the company announced an ...

ImmunityBio and NantKwest Complete Merger
09 Mar, 2021 FinancialContent

ImmunityBio, Inc. and NantKwest, Inc. (NASDAQ: NK), today announced the completion of their previously announced 100% stock-for-stock merger. This follows the satisfaction of all customary closing conditions, including approval of the merger by a majority of unaffiliated shareholders of NantKwest at its Special Meeting held on March 8, 2021. The combined company will operate under the name ImmunityBio, Inc. (“ImmunityBio”) and its shares of common stock will commence trading on NASDAQ on March 10, 2021 under the new ticker “IBRX.”

61 Stocks Moving In Tuesday's Mid-Day Session
09 Mar, 2021 FinancialContent

Gainers INVO Bioscience, Inc. (NASDAQ: INVO) shares jumped 230.6% to $10.28 after the company announced an amendment under its ...

38 Stocks Moving in Tuesday's Pre-Market Session
09 Mar, 2021 FinancialContent

Gainers INVO Bioscience, Inc. (NASDAQ: INVO) shares rose 108.4% to $6.48 in pre-market trading after the company announced an ...

Stockholders of NantKwest Approve Merger With ImmunityBio
08 Mar, 2021 FinancialContent

NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that its stockholders approved by the required vote each of the proposals related to the pending merger of NantKwest and ImmunityBio, Inc. presented at the special meeting of stockholders held earlier in the day, including approval of the merger by a majority of unaffiliated stockholders of NantKwest. Final voting results for NantKwest’s special meeting of stockholders will be disclosed in a Form 8-K to be filed by NantKwest with the Securities and Exchange Commission.

ImmunityBio and NantKwest Begin Dosing Participants in Global Trials for Novel COVID-19 Vaccine; Subcutaneous Route in South Africa, Oral and Sublingual in the U.S.
08 Mar, 2021 FinancialContent

ImmunityBio, Inc., a privately-held immunotherapy company, and NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced the first cohorts of their South Africa and U.S. COVID-19 vaccine trials have received their initial doses of the company’s T-cell-based COVID-19 vaccine candidate, hAd5. This candidate is unique in targeting both the spike (S) and nucleocapsid (N) proteins of the SARS-CoV-2 virus. These trials will determine which route combination provides the strongest immune response and long-term immunity, as well as the vaccine candidate’s effectiveness against the growing number of mutated variants of the virus.

AlphaBio In-licenses Off-the-Shelf NK/T-Cell Technology for Cancer
08 Mar, 2021 FinancialContent

Shanghai's AlphaBio in-licensed Asia rights to Wugen's novel universal natural killer (NK) and T-cell therapies for cancer. The agreement will include rights to manufacture universal off-the-shelf memory NK and CAR-T cells to treat solid tumors, T-cell malignancies, acute myeloid leukemia and multiple myeloma. The technology is designed to overcome the drawbacks of CAR-T drugs. Wugen acquired the technologies from Washington University of St. Louis, MO, where both entities are located. So far, Wugen remains a pre-clinical company. More details.... Share this with colleagues:

61 Biggest Movers From Yesterday
03 Mar, 2021 FinancialContent

Gainers Rocket Companies, Inc. (NYSE: RKT) shares jumped 71.2% to close at $41.60 on Tuesday on continued strength after the ...

Cramer Advises Viewers On First Solar, Madison Square Garden Sports And More
28 Feb, 2021 FinancialContent

Jim Cramer spoke on CNBC's "Mad Money Lightning Round" about Nantkwest Inc (NASDAQ: NK). He said it is a great ...

SHAREHOLDER ALERT: Barr Law Group Investigating NK, IQDNX, JELD, and MDXG; Shareholders are Encouraged to Contact the Firm
26 Feb, 2021 FinancialContent
All Three Independent Proxy Advisory Firms – ISS, Glass Lewis and Egan-Jones – Recommend NantKwest Stockholders Vote “FOR” the Pending Merger With ImmunityBio
25 Feb, 2021 FinancialContent

NantKwest, Inc. (NASDAQ: NK), a clinical-stage, natural killer cell-based therapeutics company, today announced that leading independent proxy advisory firms Institutional Shareholder Services Inc. (“ISS”), Glass, Lewis & Co., LLC (“Glass Lewis”), and Egan-Jones Proxy Services (“Egan-Jones”) have recommended NantKwest stockholders vote “FOR” the pending merger with ImmunityBio.

ImmunityBio Appoints John Brennan and Wesley Clark to Board of Directors
24 Feb, 2021 FinancialContent

ImmunityBio, Inc., a privately-held immunotherapy company, today announced the appointment of John Brennan, former Central Intelligence Agency Director, and Wesley Clark, retired U.S. Army General, to the company’s board of directors, effective immediately.

88 Biggest Movers From Yesterday
24 Feb, 2021 FinancialContent

Gainers Solid Biosciences Inc. (NASDAQ: SLDB) shares surged 41.8% to close at $9.74 on above-average session volume. TimkenSteel ...

Notable Tuesday Option Activity: NK, SAFM, PRPL
23 Feb, 2021 FinancialContent

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in NantKwest Inc (NK), where a total volume of 7,877 contracts has been traded thus far today, a contract volume which is representative of approximately 787,700 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 58.6% of NK's average daily trading volume over the past month, of 1.3 million shares..

12 Health Care Stocks Moving In Tuesday's Intraday Session
23 Feb, 2021 FinancialContent

Gainers Sunesis Pharmaceuticals (NASDAQ:SNSS) stock rose 25.84% to $4.48 during Tuesday's regular session. Trading ...

The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts
23 Feb, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Merger Investigation
20 Feb, 2021 FinancialContent
The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko
19 Feb, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Nantkwest - Stock Of The Day
18 Feb, 2021 FinancialContent

Revenue expected to grow 132.50% next year. Earnings estimated to decrease at a compounded annual rate of 1.70% for the next 5 years.

INVESTIGATION ALERT: Halper Sadeh LLP Investigates MDCA, CLGX, SYNC, NK; Shareholders Are Encouraged to Contact the Firm
17 Feb, 2021 FinancialContent
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal
17 Feb, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

ImmunityBio Announces ASCO Genitourinary Cancer Symposium Presentation of Phase 2/3 Trial for BCG Unresponsive Non-Muscle Invasive Bladder Cancer CIS with 71% Complete Response Rate
16 Feb, 2021 FinancialContent

ImmunityBio, Inc., a privately-held immunotherapy company, today announced the oral presentation of “Phase II/III clinical results of IL-15RαFc superagonist N-803 with BCG in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) carcinoma in situ (CIS) patients (Cohort A)” during a session at the Genitourinary Cancers Symposium sponsored by the American Society of Clinical Oncology (ASCO).

64 Biggest Movers From Friday
16 Feb, 2021 FinancialContent

Gainers Wunong Net Technology Company Limited (NYSE: WNW) jumped 102.3% to close at $32.19 on Friday. Talis Biomedical ...

Lifshitz Law Firm, P.C. Announces Investigation of CATM, FFG, NK, and VIE
14 Feb, 2021 FinancialContent
12 Health Care Stocks Moving In Friday's Intraday Session
12 Feb, 2021 FinancialContent

Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 84.54% to $3.01 during Friday's regular session. Trading volume for this ...

12 Health Care Stocks Moving In Friday's Pre-Market Session
12 Feb, 2021 FinancialContent

Gainers Artelo Biosciences (NASDAQ:ARTL) shares rose 61.34% to $2.63 during Friday's pre-market session. The company's market cap ...

The Daily Biotech Pulse: European Regulatory Nod For Xeris, Amicus Falls On Data, 4 IPOs, FDA Decision For Mallinckrodt's StrataGraft Delayed
12 Feb, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

NantKwest, Inc (NK) is a NASDAQ Common Stock listed in , ,

970x250